SAVINGS DEADLINE EXPIRES:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center ViennaGavin Bennett, PhDSenior Director, Drug Development at Bicycle Therapeutics Ltd
Profile
I’m the Programme Leader for BT5528, a Bicycle Toxin Conjugate in clinical development. After previous jobs developing small and large molecules for a variety of diseases and companies, I joined Bicycle in 2013 as an in vivo pharmacologist, and have been involved in the Development of Bicycle conjugates from concept to clinic.
Agenda Sessions
Bicycle Conjugates to Target Solid Tumors
, 16:00View Session